INTRODUCTION
============

Restless legs syndrome (RLS) is a sleep and sensorimotor disorder, the prevalence of which varies depending on the population analyzed and methods applied. However, it is generally estimated that 5--10% of the adult population suffers from RLS worldwide \[[@b1-pi-2018-02-26],[@b2-pi-2018-02-26]\]. Typical clinical manifestations of RLS include uncomfortable sensations in, and irresistible urges to move, the legs. These symptoms are either aggravated or start at night, and are temporarily relieved by leg movements. RLS is a chronic and distressing disorder that frequently causes insomnia, impairs sleep quality and quality of life, and carries psychological consequences \[[@b3-pi-2018-02-26],[@b4-pi-2018-02-26]\]. In addition, RLS has been suggested to be associated with various comorbidities, especially cardiovascular disease (CVD) and related conditions \[[@b5-pi-2018-02-26]\].

CVD as a comorbidity in patients with RLS has been determined in many cross-sectional studies with large sample sizes \[[@b6-pi-2018-02-26]-[@b8-pi-2018-02-26]\], although the findings of prospective studies have been inconsistent \[[@b9-pi-2018-02-26],[@b10-pi-2018-02-26]\]. The potential underlying mechanism of an increased risk of CVD in RLS is not clear, but may involve hypertension, as periodic limb movements during sleep (PLMS) were shown to be related to blood pressure increases \[[@b11-pi-2018-02-26],[@b12-pi-2018-02-26]\]. Alternatively, a blunted nocturnal blood pressure dipping response due to RLS- and PLMS-related insomnia may cause hypertension and CVD \[[@b13-pi-2018-02-26]\]. Observational studies have also reported a relationship between RLS or PLMS and high nocturnal blood pressure \[[@b14-pi-2018-02-26]\], as well as daytime hypertension \[[@b15-pi-2018-02-26]\].

Most epidemiologic studies of the incidence of hypertension in RLS were cross-sectional in design \[[@b6-pi-2018-02-26],[@b7-pi-2018-02-26],[@b16-pi-2018-02-26]-[@b24-pi-2018-02-26]\], although a few cohort studies \[[@b25-pi-2018-02-26]\] have also been published. The prevalence of hypertension in RLS was high in some studies \[[@b16-pi-2018-02-26],[@b17-pi-2018-02-26],[@b23-pi-2018-02-26],[@b25-pi-2018-02-26]\], whereas the results were contradictory in others \[[@b6-pi-2018-02-26],[@b7-pi-2018-02-26],[@b18-pi-2018-02-26]-[@b22-pi-2018-02-26],[@b24-pi-2018-02-26]\]. Therefore, the present work consisted of a comprehensive meta-analysis of the prevalence of hypertension in RLS versus non-RLS patients, and examined the potential reasons for the previous inconsistent findings in sub-group analyses.

METHODS
=======

Information sources and search strategy
---------------------------------------

The PUBMED, EMBASE, and Cochrane Library databases were searched comprehensively from their inception until October 28, 2016. No language restrictions were applied. The Korean electronic databases (Korean Studies Information Service System, the National Assembly Library, DBpia, and RISS4U) were searched for the same period. All searches were conducted as suggested by the Meta-analysis of Observational Studies in Epidemiology \[[@b26-pi-2018-02-26]\]. Ethical approval was not required for this analysis because the data used in this study were extracted from the published literature.

Study selection and eligibility criteria
----------------------------------------

The search terms were related to RLS ('restless legs syndrome' or 'RLS' or 'Ekbom syndrome'), hypertension ('hyperten\*' or 'high blood pressure'), and outcomes ('risk' or 'incidence' or 'ratio'). In PUBMED, the key words were ((("risk"\[MeSH Terms\] OR "risk"\[All Fields\]) OR ("epidemiology"\[Subheading\] OR "epidemiology" \[All Fields\] OR "incidence" \[All Fields\] OR "incidence" \[MeSH Terms\]) OR ("Ratio (Oxf)" \[Journal\] OR "ratio" \[All Fields\])) AND ("restless legs syndrome" \[All Fields\] OR RLS\[All Fields\] OR "Ekbom syndrome" \[All Fields\])) AND ((hyperten\*\[All Fields\] OR "high blood pressure"\[All Fields\]). In EMBASE, the key words were ('risk'/exp OR risk OR 'incidence'/exp OR incidence OR; 'ratio'/exp OR ratio) AND ('restless legs syndrome'/exp OR 'restless legs syndrome' OR rls OR 'ekbom syndrome'/exp OR 'ekbom syndrome') AND (hyperten\* OR 'high blood pressure'/exp OR 'high blood pressure'). The reference lists of relevant articles were reviewed to identify additional papers not identified in the database searches. Case reports, reviews, and non-peer-reviewed sources (e.g., conference abstracts, author replies) were excluded. Original observational studies of the association between RLS and hypertension prevalence in humans were included, as were studies in which the data were evaluated using the International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria \[[@b27-pi-2018-02-26]\]. Studies that used different RLS diagnostic criteria or enrolled only individuals with frequent RLS symptoms were excluded, as were publications in which hypertension was a risk factor and blood pressure was a continuous variable \[[@b25-pi-2018-02-26]\].

Both a measure of association \[odds ratio (OR) and hazard ratio (HR)\] and a measure of precision \[confidence interval (CI)\] for the association between RLS and hypertension prevalence were obtained from the studies, together with the fully adjusted and unadjusted measures of association. We assumed that the HR was close to the OR because the incidence of RLS was sufficiently low for the rare disease assumption to apply \[[@b28-pi-2018-02-26]\]. In cases of multiple publications based on the same study sample, the most recent publication was reviewed.

Data extraction
---------------

All relevant articles were independently evaluated by two of the authors (IC Hwang and SG Kang), and disagreements were resolved by consensus or consultation with the third author (KS Na). The following data were selected from each study: first author, year of publication, country in which the study was performed, population and setting of the study, number of participants, study design, criteria and method for diagnosis of RLS and hypertension, OR (or HR) and 95% CI, and the confounding (and subsequently adjusted) variables. We evaluated the methodological quality of the studies using the Newcastle-Ottawa scale by means of two investigators, independently \[[@b29-pi-2018-02-26]\], and any discrepancies were resolved by consensus.

Statistical analysis
--------------------

The relationship between RLS and the prevalence of hypertension was investigated in a meta-analysis followed by a sub-group meta-analysis that took account of the following factors: study design (cross-sectional), sex, method of RLS evaluation (self-reported questionnaire vs. face-to-face interview), adjustment for potential confounders \[diabetes mellitus (DM), dyslipidemia, established CVD, body mass index, and smoking status\].

A meta-regression analysis was conducted to identify the effects of covariates, including DM, dyslipidemia, CVD, BMI, and smoking on the study results.

A pooled OR with a 95% CI was calculated based on data extracted from individual studies. To calculate the variance in the log OR from each study, the 95% CI was converted to natural log values by taking the span of the CI and dividing it by 3.92. Summary OR estimates were derived using the method of DerSimonian and Laird \[[@b30-pi-2018-02-26]\].

To test for the proportion of variation, Higgins' I^2^, which indicates the variation (%) across studies, was used. In our analyses, the DerSimonian and Laird random effects model, which is the generally accepted approach, was applied. A potential small-study effect and publication bias were assessed using Egger's test and visual inspection of funnel plot. All statistical analyses were performed with Comprehensive Meta-Analysis software (ver. 3; Biostat, Englewood, NJ, USA).

RESULTS
=======

Study selection and characteristics
-----------------------------------

A flow diagram for the identification of suitable studies (according to PRISMA) is shown in [Figure 1](#f1-pi-2018-02-26){ref-type="fig"}. Through a systematic search of the electronic database, and a manual search for articles cited in the retrieved studies, 451 articles were obtained in total. Nine studies (429,617 participants) were included in our final meta-analysis after the review process shown in [Figure 1](#f1-pi-2018-02-26){ref-type="fig"}.

Eight of the nine studies were cross-sectional \[[@b16-pi-2018-02-26]-[@b22-pi-2018-02-26],[@b24-pi-2018-02-26]\] and one was a cohort study \[[@b25-pi-2018-02-26]\]. The most important characteristics of the studies are summarized in [Table 1](#t1-pi-2018-02-26){ref-type="table"}. We also showed the quality of all enrolled studies in the meta-analysis in [Supplementary Table 1](#SD1-pi-2018-02-26){ref-type="supplementary-material"} after assessment by the Newcastle-Ottawa scale. Most of the studies (n=7) were conducted in the USA \[[@b21-pi-2018-02-26],[@b22-pi-2018-02-26],[@b25-pi-2018-02-26]\] or in European countries \[[@b18-pi-2018-02-26]-[@b20-pi-2018-02-26],[@b24-pi-2018-02-26]\]; one study was performed in Taiwan \[[@b17-pi-2018-02-26]\] and another in Mexico \[[@b16-pi-2018-02-26]\]. Adjustment was made for age in all of the studies. Sex was adjusted for in four studies; in the other five studies, only males (n=2) or females (n=3) were enrolled. Adjustments for other confounders varied according to the nature of the study.

Meta-analysis
-------------

Individuals with RLS were associated with a higher prevalence of hypertension (OR=1.13, 95% CI=1.04--1.23, p=0.003), as shown in [Figure 2](#f2-pi-2018-02-26){ref-type="fig"} and [Table 2](#t2-pi-2018-02-26){ref-type="table"}. In cross-sectional studies, the prevalence of hypertension in RLS patients was significantly higher (OR=1.12, 95% CI=1.01--1.24, p=0.028).

As shown in [Figure 3](#f3-pi-2018-02-26){ref-type="fig"}, visual inspection of the funnel plot and the application of pseudo-95% confidence limits and Egger's bias (t=0.61, 95% CI=-1.70--2.87, p=0.562) did not suggest publication bias.

Sub-group analyses
------------------

In the sub-group analyses by the RLS evaluation method, higher prevalence of hypertension in RLS patients was determined only in studies using self-reported questionnaires (OR=1.13, 95% CI=1.01--1.27, p=0.036), and not in those employing face-to-face interviews (OR=1.08, 95% CI=0.80--1.45, p=0.615).

There was a higher prevalence of hypertension in RLS patients in unadjusted studies for DM (OR=1.25, 95% CI=1.00--1.55, p=0.049), dyslipidemia (OR=1.33, 95% CI=1.04--1.72, p=0.026), and established CVD (OR=1.14, 95% CI=1.04--1.25, p=0.005). However, the relationships between the prevalence of hypertension and RLS were not significant in studies adjusted for the same confounders. In terms of smoking status, a higher prevalence of hypertension was observed in RLS patients only in studies adjusted for smoking status (OR=1.11, 95% CI=1.03--1.20, p=0.005); no higher prevalence of hypertension was observed in RLS patients in studies that were not adjusted for smoking status.

While a significant relationship between RLS and hypertension was found in studies that enrolled only females (OR=1.12, 95% CI=1.03--1.22, p=0.011), this was not the case in those that enrolled only males (OR=1.13, 95% CI=0.77--1.66, p=0.518).

In the meta-regression analysis to investigate the impact of the covariates on the study results, smoking had a significant impact on the study results ([Table 3](#t3-pi-2018-02-26){ref-type="table"}).

DISCUSSION
==========

The results of our meta-analysis indicate a higher prevalence of hypertension in individuals with RLS, although the results were only marginally significant. The importance of our study is that it examined the inconsistent findings of previous studies and allowed us to conclude that RLS, which is a common condition, not only causes distress but is also associated with a higher prevalence of hypertension, one of the most significant risk factors for CVD. However, strong support for this result could not be obtained because of the small number of prospective studies included, and because the relationship between RLS and hypertension was no longer significant after adjusting for the confounders of metabolic syndrome, such as DM and dyslipidemia.

Although the physiological mechanism underlying the association between RLS and hypertension is not clear, putative mechanisms suggested by previous studies include: 1) 80% of RLS patients have PLMS, a condition that, during sleep, increases heart rate and blood pressure, both of which are risk factors for hypertension \[[@b31-pi-2018-02-26]-[@b33-pi-2018-02-26]\]. 2) RLS symptoms cause distress and sleep impairment, and therefore stress, which can activate the autonomic nervous system, induce arterial baroreflex dysfunction, and increase the synthesis of catecholamines \[[@b14-pi-2018-02-26],[@b34-pi-2018-02-26],[@b35-pi-2018-02-26]\]. 3) The activation by RLS of the hypothalamic-pituitary-adrenal axis is related to increased nocturnal cortisol and blood pressure levels \[[@b36-pi-2018-02-26]\].

Since most of the studies included in our meta-analysis were cross-sectional in design, the nature of the association between RLS and hypertension could not be established. The cohort study performed in the USA found an increased risk of hypertension in RLS patients \[[@b25-pi-2018-02-26]\]. Thus, well-designed prospective cohort studies are needed to examine the risk of hypertension in RLS. To be conclusive, these studies should include only patients with idiopathic RLS and exclude all those with secondary RLS, including RLS due to DM neuropathy and renal failure, both of which are risk factors for hypertension. We should not depend entirely on IRLSSG criteria, which cannot differentiate between primary and secondary RLS, as secondary RLS, including DM neuropathy, and renal failure, were associated with an increased hypertension risk in a previous cohort study \[[@b25-pi-2018-02-26]\]. Moreover, the association between RLS and hypertension may be in the opposite direction, that is, hypertension could be a risk factor for RLS; vascular changes due to hypertension may induce RLS symptoms and antihypertensive medication may cause side effects that are similar to RLS symptoms \[[@b7-pi-2018-02-26],[@b23-pi-2018-02-26]\]. However, this reversed association was not supported by other studies that used a prospective design \[[@b37-pi-2018-02-26],[@b38-pi-2018-02-26]\].

DM, dyslipidemia, and established comorbid CVD may be important pathways linking RLS and hypertension, as they showed a significant association in studies that were unadjusted for these confounders, but not after adjustment. Although there is some debate, a relationship between DM and RLS has been reported by many studies, and DM neuropathy is one of the common causes of secondary RLS \[[@b39-pi-2018-02-26]\]. DM, dyslipidemia, and hypertension are the main components of metabolic syndrome and important risk factors for CVD. Therefore, to investigate the direct relationship between RLS and hypertension, basic research that adjusts for these confounders is needed. Future prospective studies on the association between RLS and hypertension should control for the use of antihypertensive medication \[[@b40-pi-2018-02-26]\], given that beta-blockers and calcium channel blockers can ameliorate, but also aggravate, RLS symptoms \[[@b41-pi-2018-02-26]\]. Greater attention must be paid to managing the risk factors of metabolic syndrome and adequately treating RLS.

Our study also suggests that certain lifestyle variables (smoking status and obesity) greatly influence the association between RLS and hypertension. Smoking status impacted the study results in the meta-regression analysis. This can, in part, be explained by reverse causation, as patients with hypertension are more likely to adopt healthy behaviors than non-hypertensive controls \[[@b42-pi-2018-02-26]\].

In the sub-group analyses of studies that enrolled only females \[[@b16-pi-2018-02-26],[@b20-pi-2018-02-26],[@b22-pi-2018-02-26]\] there was a higher prevalence of hypertension in those with RLS, whereas this was not demonstrated in the studies that enrolled only males \[[@b19-pi-2018-02-26],[@b21-pi-2018-02-26]\]. The following is proposed: 1) higher susceptibility of females to insomnia and arousal \[[@b43-pi-2018-02-26]\]; 2) higher prevalence of RLS in females \[[@b4-pi-2018-02-26]\]; 3) greater variability of PLMS \[[@b44-pi-2018-02-26]\] and the higher amplitude of bradycardia (which follows tachycardia) in females in response to PLMS \[[@b45-pi-2018-02-26]\]; and 4) sex-related differences in sleep-arousal and circadian rhythms in the hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal axes \[[@b46-pi-2018-02-26]\]. However, whether there is a sex difference in the prevalence of hypertension remains unclear, because the number of studies in both sets of analyses was small and the characteristics of the study population varied. In addition, the results of studies conducted only on males show a wide 95% CI (0.77--1.66), which does not rule out the possibility of a false negative.

The association of hypertension with RLS was significant in the studies based on self-report evaluations of RLS, but not in those in which evaluations were made during face-to-face interviews. Self-reporting might be vulnerable to recall bias and misclassification. Also, considering the wide 95% CI (0.82--1.43) of the studies employing face-to-face interviews, the possibility of type II error due to the small sample size cannot be ruled out.

The limitation in this study was the need to adopt only IRLSSG diagnostic criteria, which are the most commonly used RLS criteria, because we wanted to select studies with similar study designs to ensure homogeneity. Therefore, we could not include studies with different frequency or severity criteria for the RLS diagnosis. Thus, we were unable to investigate the difference in prevalence of hypertension according to the severity and frequency of RLS. One study reported that the higher the frequency of RLS, the higher the risk of hypertension \[[@b16-pi-2018-02-26]\]. Thus, whether these two conditions exhibit an exposure-response relationship merits further research and clinical investigation. The small number of studies also hindered assessment of the prevalence of hypertension in patients with primary versus secondary RLS, although a difference was demonstrated previously \[[@b25-pi-2018-02-26]\]. On the other hand, we used funnel plots and Egger's test to examine publication bias. It is generally recommended to use such methods when the number of individual studies is substantially more than 10 \[[@b47-pi-2018-02-26]\]. Otherwise, the funnel plot and Egger's test might have low statistical power and ability to detect actual asymmetry in the funnel plot. Hence, the results from the funnel plot and the Egger's test might not have fully distinguished asymmetry in the included studies.

In summary, the results of our pooled analysis suggest that individuals with RLS show a higher prevalence of hypertension, but well-designed, prospective studies are needed to confirm this finding. Future prospective research should differentiate between primary and secondary RLS and quantify the severity and frequency of RLS to investigate the relationship between RLS and hypertension more accurately.
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###### 

Characteristics and designs of the studies included in this meta-analysis

  Source and study publication year                Country   Population, setting, number of participants                                                                       Design                 RLS diagnosis^[\*](#tfn1-pi-2018-02-26){ref-type="table-fn"}^   Hypertension diagnosis                                           Confounders adjusted for                                                                                                                                                                                                                                                                       Newcastle-Ottawa Scale
  ------------------------------------------------ --------- ----------------------------------------------------------------------------------------------------------------- ---------------------- --------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------
  Catzin-Kuhlmann, 2015 \[[@b16-pi-2018-02-26]\]   Mexico    54,925 females (9,230 RLS vs no RLS 45,695)                                                                       Cross-sectional        Self-report                                                     Self-report^[\*](#tfn1-pi-2018-02-26){ref-type="table-fn"}^      Age, sex (only female participants), family history of MI, hormonal contraceptive, menopausal status, BMI, physical activity, smoking, migraine, and consumption of alcohol, bread, fruits, vegetables, and total energy                                                                       7
  Chen, 2010 \[[@b17-pi-2018-02-26]\]              Taiwan    CATI telephone interview 4,011 subjects (RLS 64 vs no RLS 3,947)                                                  Cross-sectional        Self-report                                                     Self-report^[†](#tfn2-pi-2018-02-26){ref-type="table-fn"}^       Age, sex, BMI                                                                                                                                                                                                                                                                                  4
  Giannini, 2014 \[[@b18-pi-2018-02-26]\]          Italy     1,709 subjects (RLS 170 vs no RLS 1,539)                                                                          Cross-sectional        Face-to-face interviews                                         Self-report^[†](#tfn2-pi-2018-02-26){ref-type="table-fn"}^       Age, sex, DM, MI, dyslipidemia, BMI                                                                                                                                                                                                                                                            5
  Szentkirályi, 2013 \[[@b24-pi-2018-02-26]\]      Germany   Dortmund health study: 1,312 (RLS at baseline 7.4%) Study of health in Pomerania: 4,308 (RLS at baseline 10.1%)   Cross-sectional        Face-to-face interviews                                         Self-report^[†](#tfn2-pi-2018-02-26){ref-type="table-fn"}^       Age, sex, education, alcohol consumption, smoking, physical activity, hemoglobin, glomerular filtration rate, cholesterol level and cardiovascular diseases except for the respective outcome                                                                                                  6
  Ulfberg, 2001 \[[@b19-pi-2018-02-26]\]           Sweden    2,608 males (RLS 181, without RLS 2,427)                                                                          Cross-sectional        Self-report                                                     Self-report^[‡](#tfn3-pi-2018-02-26){ref-type="table-fn"}^       Age, sex (only male participants), witnessed apneas, smoking, and alcohol consumption                                                                                                                                                                                                          5
  Wesstrom, 2008 \[[@b20-pi-2018-02-26]\]          Sweden    3,501 women (551 primary RLS vs 2,950 no RLS)                                                                     Cross-sectional        Self-report                                                     Self-report^[‡](#tfn3-pi-2018-02-26){ref-type="table-fn"}^       Age, sex (only female participants), smoking, alcohol and coffee consumption, use of sleeping pills                                                                                                                                                                                            5
  Winter, 2013, male \[[@b21-pi-2018-02-26]\]      USA       US Physicians' Health Studies I and II. 22,786 males (RLS 1,710 vs. no RLS 21,076)                                Cross-sectional        Self-report                                                     Self-report^[§](#tfn4-pi-2018-02-26){ref-type="table-fn"}^       Age, sex (only male participants), randomized aspirin assignment, all vascular risk factors (DM, hypercholesterolemia, parental history of MI before age 60 years, alcohol consumption, smoking, exercise, BMI)                                                                                7
  Winter, 2013, female \[[@b22-pi-2018-02-26]\]    USA       US health care professionals 30,262 females (RLS 3,624 vs. no RLS 26,638)                                         Cross-sectional        Self-report                                                     Self-report^[§](#tfn4-pi-2018-02-26){ref-type="table-fn"}^       Age, sex (only female participants), randomized aspirin assignment, postmenopausal status, postmenopausal hormone use, oral contraceptive use, all vascular risk factors (DM, hypercholesterolemia, parental history of MI before age 60 years, alcohol consumption, smoking, exercise, BMI)   7
  Van Den Eeden, 2015 \[[@b25-pi-2018-02-26]\]     USA       Kaiser Permanente Northern California (KPNC) cohort Primary RLS 7,621 vs. 296,574 controls                        Retrospective cohort   Medical records, diagnoses and survey dataǁ                     Medical records^[†](#tfn2-pi-2018-02-26){ref-type="table-fn"}^   Age, race, sex, smoking, BMI, DM, hyperlipidemia treatment                                                                                                                                                                                                                                     8

The number of references is the same as those listed in the manuscript.

diagnosis of RLS was made based on the IRLSSG criteria,

hypertension was defined as a diagnosis established at any time by a physician or treatment with antihypertensive medication,

hypertension was defined as a diagnosis established at any time by a physician,

hypertension was defined as blood pressure≥140 mm Hg or diastolic blood pressure≥90 mm Hg or antihypertensive treatment, ǁmedical record diagnoses and survey for the expanded set of questions on RLS based on the IRLSSG criteria.

RLS: restless legs syndrome, BMI: body mass index, DM: diabetes mellitus, MI: myocardial infarction

###### 

Hypertension risk among restless legs syndrome (RLS) patients by study design and confounders

  Analyses                                                                                                                    No. of studies   Summary OR (95% CI)                                                                                                 p value                                                Proportion of variation, I^2^   Model
  --------------------------------------------------------------------------------------------------------------------------- ---------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ------------------------------- ----------------
  Overall                                                                                                                     9                1.13 (1.04--1.23)^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^                                                    0.003^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^   58.9%                           Random-effects
  Study design                                                                                                                                                                                                                                                                                                                                            
   Cross-sectional \[[@b16-pi-2018-02-26]-[@b22-pi-2018-02-26],[@b24-pi-2018-02-26]\]                                         8                1.12 (1.01--1.24)^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^                                                    0.028^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^   58.6%                           Random-effects
   Cohort \[[@b25-pi-2018-02-26]\]                                                                                            1                1\. 2^[\*](#tfn5-pi-2018-02-26){ref-type="table-fn"}^ (1.10--1.30)^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^                                                                                          
  Limited to                                                                                                                                                                                                                                                                                                                                              
   Male \[[@b19-pi-2018-02-26],[@b21-pi-2018-02-26]\]                                                                         2                1.13 (0.77--1.66)                                                                                                   0.518                                                  61.9%                           Random-effects
   Female \[[@b16-pi-2018-02-26],[@b20-pi-2018-02-26],[@b22-pi-2018-02-26]\]                                                  3                1.12 (1.03--1.22)^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^                                                    0.011^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^   51.1%                           Random-effects
  RLS diagnosis by                                                                                                                                                                                                                                                                                                                                        
   Self-report \[[@b16-pi-2018-02-26],[@b17-pi-2018-02-26],[@b19-pi-2018-02-26]-[@b22-pi-2018-02-26]\]                        6                1.13 (1.01--1.27)^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^                                                    0.036^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^   72.4%                           Random-effects
   Face to face interview \[[@b18-pi-2018-02-26],[@b24-pi-2018-02-26]\]                                                       2                1.08 (0.80--1.45)                                                                                                   0.615                                                  0%                              Random-effects
  Potential confounders                                                                                                                                                                                                                                                                                                                                   
   DM                                                                                                                                                                                                                                                                                                                                                     
    Unadjusted \[[@b16-pi-2018-02-26],[@b17-pi-2018-02-26],[@b19-pi-2018-02-26],[@b20-pi-2018-02-26],[@b24-pi-2018-02-26]\]   5                1.25 (1.00--1.55)^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^                                                    0.049^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^   58.2%                           Random-effects
    Adjusted \[[@b18-pi-2018-02-26],[@b21-pi-2018-02-26],[@b22-pi-2018-02-26],[@b25-pi-2018-02-26]\]                          4                1.10 (0.99--1.21)                                                                                                   0.077                                                  66.2%                           Random-effects
   Dyslipidemia                                                                                                                                                                                                                                                                                                                                           
    Unadjusted \[[@b16-pi-2018-02-26],[@b17-pi-2018-02-26],[@b19-pi-2018-02-26],[@b20-pi-2018-02-26]\]                        4                1.33 (1.04--1.72)^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^                                                    0.026^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^   62.6%                           Random-effects
    Adjusted \[[@b18-pi-2018-02-26],[@b21-pi-2018-02-26],[@b22-pi-2018-02-26],[@b24-pi-2018-02-26],[@b25-pi-2018-02-26]\]     5                1.08 (0.99--1.19)                                                                                                   0.092                                                  58.3%                           Random-effects
   Established CVD                                                                                                                                                                                                                                                                                                                                        
    Unadjusted \[[@b16-pi-2018-02-26],[@b17-pi-2018-02-26],[@b19-pi-2018-02-26]-[@b22-pi-2018-02-26],[@b25-pi-2018-02-26]\]   7                1.14 (1.04--1.25)^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^                                                    0.005^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^   70.9%                           Random-effects
    Adjusted \[[@b18-pi-2018-02-26],[@b24-pi-2018-02-26]\]                                                                    2                1.08 (0.80--1.45)                                                                                                   0.615                                                  0%                              Random-effects
   BMI                                                                                                                                                                                                                                                                                                                                                    
    Unadjusted \[[@b19-pi-2018-02-26],[@b20-pi-2018-02-26],[@b24-pi-2018-02-26]\]                                             3                1.10 (0.87--1.40)                                                                                                   0.4                                                    0%                              Random-effects
    Adjusted \[[@b16-pi-2018-02-26]-[@b18-pi-2018-02-26],[@b21-pi-2018-02-26],[@b22-pi-2018-02-26],[@b25-pi-2018-02-26]\]     6                1.14 (1.04--1.26)^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^                                                    0.007^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^   74.4%                           Random-effects
   Smoking status                                                                                                                                                                                                                                                                                                                                         
    Unadjusted \[[@b17-pi-2018-02-26],[@b18-pi-2018-02-26]\]                                                                  2                1.68 (0.88--3.23)                                                                                                   0.118                                                  75.1%                           Random-effects
    Adjusted \[[@b16-pi-2018-02-26],[@b19-pi-2018-02-26]-[@b22-pi-2018-02-26],[@b24-pi-2018-02-26],[@b25-pi-2018-02-26]\]     7                1.11 (1.03--1.20)^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^                                                    0.005^[†](#tfn6-pi-2018-02-26){ref-type="table-fn"}^   56.6%                           Random-effects

The numbers of references are same to those of the reference list in the manuscript.

hazard ratio,

statistically significant results.

OR: odds ratio, CI: confidence interval, DM: diabetes mellitus, CVD: cardiovascular disease, BMI: body mass index

###### 

Meta-regression to identify the effects of covariates on the study results

  Covariates     Coefficient   Standard error   95% lower   95% upper   Z value   p value
  -------------- ------------- ---------------- ----------- ----------- --------- --------------------------------------------------------
  Intercept      -0.5031       0.3625           -1.2135     0.2073      -1.39     0.1651
  DM             0.3039        0.6815           -1.0319     1.6397      0.45      0.6557
  Dyslipidemia   -0.2124       0.6889           -1.5626     1.1378      -0.31     0.7579
  CVD            0.5772        0.3661           -0.1404     1.2947      1.58      0.1149
  BMI            0.0129        0.1694           -0.3191     0.3449      0.08      0.9391
  Smoking        0.7183        0.2975           0.1352      1.3013      2.41      0.0158^[\*](#tfn7-pi-2018-02-26){ref-type="table-fn"}^

statistically significant results.

DM: diabetes mellitus, CVD: cardiovascular disease, BMI: body mass index
